Skip to main content

Table 1 Demographic and pretreatment clinical characteristics

From: Analysis of long-term oncological results of clinical versus pathological responses after neoadjuvant treatment in locally advanced rectal cancer

 

Group 1

Group 2

p value

cCR

pCR

n patients (%)

26 (54.2)

22 (45.8)

 

Gender (M/F)

13/13

8/14

 

Age (years), median (range)

59 (32–82)

55 (26–73)

0.2975

Distance from anal verge (cm), mean (range)

5 (1–12)

7 (2–12)

0.32

T1–2, n (%)

8 (31)

4 (18)

0.5035

T3–4, n (%)

18 (69)

18 (82)

0.5035

cStage III (N+), n (%)

10 (38)

16 (72)

0.04

CRM+, n (%)

7 (27)

13 (59)

0.0515

EMVI+, n (%)

4 (15)

11 (50)

0.0235

LPLN+, n (%)

5 (19)

3 (14)

0.8969

CEA, > 5 ng/dl, n (%)

3 (11)

4 (18)

0.8108

Induction XELOX 3 courses, n (%)

6 (23)

5 (23)

0.7521

Median follow-up—months (range)

47 (6–94)

49.5 (3–112)

0.7848

  1. cCR clinical complete response, pCR pathological complete response, F female, M male, N+ lymph nodes suspected of malignancy, CRM+ circumferential resection margin involved, EMVI + extramural vascular invasion, LPLN lateral pelvic lymph nodes, CEA carcinoembryonic antigen, NS not significant